We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Read MoreHide Full Article
Key Takeaways
Zentalis advanced azenosertib with pivotal studies targeting cyclin E1-positive PROC.
ZNTL expects DENALI enrollment completion and topline data by the end of 2026 to support approval efforts.
Zentalis is expanding azenosertib into combination studies and additional tumor types, including TNBC.
Zentalis Pharmaceuticals'(ZNTL - Free Report) shares have gained 28% over the past three months, fueled by investor optimism surrounding its lead oncology candidate, azenosertib.
Azenosertib Drives ZNTL's Ovarian Cancer Push
Azenosertib is Zentalis’ potential first-in-class WEE1 inhibitor being developed as a biomarker-driven oral therapy for ovarian cancer and additional tumor types. Based on interim data from part 2a, which demonstrated a favorable benefit-risk profile, Zentalis selected the 400 mg once-daily, 5-days-on/2-days-off (400 mg QD 5:2) regimen in April as the pivotal dose for azenosertib monotherapy for its registration-intended DENALI phase II clinical program to treat patients with cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Management expects to complete enrollment across all DENALI part 2 cohorts and announce top-line data by the end of 2026, which could support an accelerated approval pathway, subject to positive data and FDA feedback.
Further supporting its regulatory strategy, Zentalis dosed the first patient in the phase III ASPENOVA confirmatory study in May. The study compares azenosertib monotherapy with the investigator's choice of standard-of-care chemotherapy in patients with cyclin E1-positive PROC and is designed to support the full FDA approval and potential global regulatory filings.
The FDA granted previously Fast Track Designation to azenosertib for the treatment of patients with cyclin E1-positive PROC.
Year to date, Zentalis shares have skyrocketed 278.5% compared with the industry’s 3% growth.
Image Source: Zacks Investment Research
Broadening Pipeline Boosts ZNTL's Prospects
Beyond its pivotal monotherapy program, the ongoing multi-part phase Ib MUIR study is evaluating azenosertib-based combination therapies in ovarian cancer to expand the candidate's potential beyond monotherapy. While part one is assessing azenosertib in combination with multiple chemotherapy regimens in patients with PROC, the currently enrolling part two dose-expansion cohort is evaluating azenosertib plus bevacizumab as a maintenance therapy for patients with second-line platinum-sensitive ovarian cancer whose disease progressed during first-line PARP inhibitor maintenance therapy.
Encouraging preclinical data showed that azenosertib combinations demonstrated activity in ADC-resistant triple-negative breast cancer (TNBC), supporting its expansion beyond ovarian cancer.
Zentalis Pharmaceuticals, Inc. Price and Consensus
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.44. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 20.5% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $6.36 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $4.64 to 51 cents for 2027. AMRN shares have lost 0.1% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have soared 131.8% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Key Takeaways
Zentalis Pharmaceuticals'(ZNTL - Free Report) shares have gained 28% over the past three months, fueled by investor optimism surrounding its lead oncology candidate, azenosertib.
Azenosertib Drives ZNTL's Ovarian Cancer Push
Azenosertib is Zentalis’ potential first-in-class WEE1 inhibitor being developed as a biomarker-driven oral therapy for ovarian cancer and additional tumor types. Based on interim data from part 2a, which demonstrated a favorable benefit-risk profile, Zentalis selected the 400 mg once-daily, 5-days-on/2-days-off (400 mg QD 5:2) regimen in April as the pivotal dose for azenosertib monotherapy for its registration-intended DENALI phase II clinical program to treat patients with cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Management expects to complete enrollment across all DENALI part 2 cohorts and announce top-line data by the end of 2026, which could support an accelerated approval pathway, subject to positive data and FDA feedback.
Further supporting its regulatory strategy, Zentalis dosed the first patient in the phase III ASPENOVA confirmatory study in May. The study compares azenosertib monotherapy with the investigator's choice of standard-of-care chemotherapy in patients with cyclin E1-positive PROC and is designed to support the full FDA approval and potential global regulatory filings.
The FDA granted previously Fast Track Designation to azenosertib for the treatment of patients with cyclin E1-positive PROC.
Year to date, Zentalis shares have skyrocketed 278.5% compared with the industry’s 3% growth.
Image Source: Zacks Investment Research
Broadening Pipeline Boosts ZNTL's Prospects
Beyond its pivotal monotherapy program, the ongoing multi-part phase Ib MUIR study is evaluating azenosertib-based combination therapies in ovarian cancer to expand the candidate's potential beyond monotherapy. While part one is assessing azenosertib in combination with multiple chemotherapy regimens in patients with PROC, the currently enrolling part two dose-expansion cohort is evaluating azenosertib plus bevacizumab as a maintenance therapy for patients with second-line platinum-sensitive ovarian cancer whose disease progressed during first-line PARP inhibitor maintenance therapy.
Encouraging preclinical data showed that azenosertib combinations demonstrated activity in ADC-resistant triple-negative breast cancer (TNBC), supporting its expansion beyond ovarian cancer.
Zentalis Pharmaceuticals, Inc. Price and Consensus
Zentalis Pharmaceuticals, Inc. price-consensus-chart | Zentalis Pharmaceuticals, Inc. Quote
ZNTL’s Zacks Rank & Stocks to Consider
Zentalis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.44. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 20.5% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $6.36 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $4.64 to 51 cents for 2027. AMRN shares have lost 0.1% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have soared 131.8% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.